Cochlear (Cochlear) Debt-to-Asset : 0.08 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Cochlear Debt-to-Asset?

Cochlear's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $27 Mil. Cochlear's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $112 Mil. Cochlear's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $1,694 Mil. Cochlear's debt to asset for the quarter that ended in Dec. 2023 was 0.08.

Cochlear Debt-to-Asset Historical Data

The historical data trend for Cochlear's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cochlear Debt-to-Asset Chart

Cochlear Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

Get a 7-Day Free Trial

0.13

0.27

0.11

0.10

0.08

Cochlear Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.11	0.10	0.10	0.08	0.08

Competitive Comparison of Cochlear's Debt-to-Asset

For the Medical Devices subindustry, Cochlear's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cochlear's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cochlear's Debt-to-Asset falls into.

Cochlear Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cochlear's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(26.309	+	109.128)	/	1723.96
	=	0.08

Cochlear's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(26.64	+	111.714)	/	1693.775
	=	0.08

Cochlear (OTCPK:CHEOF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cochlear Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cochlear's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cochlear (Cochlear) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (OTCPK:CHEOF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CHEOY:USA OC5:Germany COH:Australia

Address

1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109

Website

https://www.cochlear.com

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.